newswire, breaking biotechnology and pharma news

Tuesday, September 28, 2010 - OTC Trading Alert; Volume Leader Biotech Stocks: ($0.14-$0.25): (OTCBB: KBLB), (OTCBB: SNGX), (OTCBB: SFMI), (OTCBB: CHTL) - OTC Trading Alert; Volume Leader Biotech Stocks: ($0.14-$0.25): (OTCBB: KBLB), (OTCBB: SNGX), (OTCBB: SFMI), (OTCBB: CHTL)

Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company:
Point Roberts, WA ( Newswire) September 28, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($0.14-$0.25) include Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), Soligenix, Inc . (OTCBB: SNGX), Silver Falcon Mining, Inc. (OTCBB: SFMI), and China Tel Group Inc. (OTCBB: CHTL).

Sign up for Tomorrows Hot OTC Market Leaders Today!Email:
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link below

OTC/Market Commentary:
Sectors include Biotech Stocks
One of the OTCBB volume leader reports; Soligenix, Inc. (OTCBB: SNGX): "Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host-Disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Soligenix is also conducting an NIH-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.
Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax™ has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVax™ is also the subject of a $9.4 million NIH grant received by the Company supporting development of new heat stable vaccines.
For further information regarding Soligenix, Inc., please visit the Company's website at"

Market Snapshot: (at time of release)
Dow 10,851.74 +39.70 +0.37%
Nasdaq 2,374.76 +4.99 +0.21%
S&P 500 1,145.65 +3.49 +0.31%
10 Yr Bond(%) 2.4800% -0.3700
Oil 76.76 +0.24 +0.31%
Gold 1,287.50 -3.40 -0.26%

OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today! has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: OTC Volume Leaders on
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Request News and Info on OTC Investors - Get OTC stock quotes from Disclosure, Disclaimer/ OTC is a paid advertising client on
More Info:
Published at - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Disclaimer: The following news is paid for and /or published as information only for our readers. is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclaimer: Disclosure:

No comments:

Post a Comment